- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00003607
Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer
Phase III Randomized Study of Radiotherapy to the Prostate With or Without Radiotherapy to the Pelvis in Patients With Stage I, II, or III Adenocarcinoma of the Prostate
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether radiation therapy to the prostate and pelvis is more effective than radiation therapy to the prostate alone in treating prostate cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy to the prostate with or without radiation to the pelvis in treating patients with stage I, stage II, or stage III prostate cancer.
Studieoversikt
Detaljert beskrivelse
OBJECTIVES:
- Compare the survival without recurrence and overall survival of patients with stage I, II, or III adenocarcinoma of the prostate after receiving radiotherapy to the prostate with or without radiotherapy to the pelvis.
- Compare the toxic effects of these two regimens in these patients.
- Compare the quality of life of patients treated with these regimens.
- Determine the prognostic factors of progression in these patients.
- Analyze the site of relapse (prostate, pelvic lymph nodes, metastases) in case of progression in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified by participating center and prognostic group (poor vs good prognosis).
Patients are randomized to one of two treatment arms.
- Arm I: Patients receive pelvic irradiation plus local prostate irradiation.
- Arm II: Patients receive local prostate irradiation only. Radiotherapy in both arms is administered 5 days a week for 7 weeks.
Quality of life is assessed before therapy, 12 months after therapy, and then annually thereafter.
Patients are followed at 2 and 6 months and then every 6 months thereafter.
PROJECTED ACCRUAL: A total of 450 patients will be accrued for this study within 4 years.
Studietype
Registrering (Forventet)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
Angers, Frankrike, 49036
- Centre Paul Papin
-
Annecy, Frankrike, 74011 Cedex
- Centre Hospitalier d'Annecy
-
Bordeaux, Frankrike, 33076
- Institut Bergonié
-
Caen, Frankrike, 14076
- Centre Regional Francois Baclesse
-
Chalon Sur Saone, Frankrike, 71100
- Centre de Radiotherapie du Parc
-
Creteil, Frankrike, 94010
- Centre Hospitalier Universitaire Henri Mondor
-
Lille, Frankrike, 59020
- Centre Oscar Lambret
-
Limoges, Frankrike, 87042
- Centre Hospital Regional Universitaire de Limoges
-
Lyon, Frankrike, 69373
- Centre Léon Bérard
-
Lyon, Frankrike, 69008
- Clinique de la Sauvegarde - Clinique Jeanne D'Arc
-
Lyon, Frankrike, 69008
- Clinique de la Sauvegarde
-
Marseille, Frankrike, 13273
- Institut J. Paoli and I. Calmettes
-
Montpellier, Frankrike, 34298
- Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
-
Orleans, Frankrike, 45067
- CHR D'Orleans - Hopital de la Source
-
Paris, Frankrike
- Hôpital d'Instruction des Armées du Val de Grâce
-
Pierre Benite, Frankrike, 69495
- Centre Hospitalier Lyon Sud
-
Reims, Frankrike, 51056
- Institut Jean Godinot
-
Rennes, Frankrike, 35064
- Centre Eugène Marquis
-
Roanne, Frankrike, F-42300
- CHG Roanne
-
Strasbourg, Frankrike, 67010
- Clinique de l'Orangerie
-
Strasbourg, Frankrike, 67085
- Centre PAUL STRAUSS
-
Toulouse, Frankrike, 31052
- Institut Claudius Regaud
-
Valance, Frankrike, 26000
- Centre Marie Curie
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
DISEASE CHARACTERISTICS:
Histologically proven adenocarcinoma of the prostate
- Stage I (T1b or T1c, N0, M0)
- Stage II (T2, N0, M0)
- Stage III (T3, N0, M0)
Poor prognosis (high risk of lymph node invasion) defined as meeting at least 1 of the following criteria:
- Gleason score at least 7
- Prostate-specific antigen (PSA) at least 3 times upper limit of normal (ULN)
- T3 OR
Good prognosis defined as meeting 1 of the following criteria:
- T1b or T2
- T1c with Gleason score less than 7 and PSA less than 3 times ULN
- No metastases by bone scans or chest x-ray
PATIENT CHARACTERISTICS:
Age:
- 75 and under
Performance status:
- Karnofsky 70-100%
Life expectancy:
- More than 10 years
Hematopoietic:
- Not specified
Hepatic:
- Not specified
Renal:
- Not specified
Other:
- No other malignancy within the past 10 years except basal cell skin cancer
- No adenopathies
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- Not specified
Endocrine therapy:
- At least 2-6 months since prior hormonal therapy, if duration no greater than 4-8 months
- No concurrent luteinizing hormone-releasing hormone agonists
- No concurrent anti-androgen therapy
- No concurrent hormonal therapy in high-risk group
Radiotherapy:
- No prior pelvic radiotherapy
Surgery:
- No prior lymphadenectomy
- No prior surgical castration
- No prior prostatectomy
- At least 1 month since prior transurethral resection
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studiestol: Pascal Pommier, MD, Centre Léon Bérard
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Pommier P, Chabaud S, Lagrange JL, Richaud P, Lesaunier F, Le Prise E, Wagner JP, Hay MH, Beckendorf V, Suchaud JP, Pabot du Chatelard PM, Bernier V, Voirin N, Perol D, Carrie C. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol. 2007 Dec 1;25(34):5366-73. doi: 10.1200/JCO.2006.10.5171.
- Pommier P, Perol D, Lagrange J, et al.: Does pelvis and prostate radiation therapy compared to prostate radiation therapy alone improve survival in patients with non metastatic prostate carcinoma? Preliminary results of the prospective randomized GETUG 01 trial. [Abstract] Int J Radiat Oncol Biol Phys 63 (Suppl 1): A-33, S19, 2005.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CDR0000066684
- FRE-FNCLCC-GETUG-01
- EU-98029
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på strålebehandling
-
Alpha Tau Medical LTD.RekrutteringLungekreft | Tilbakevendende lungekreftIsrael
-
Alpha Tau Medical LTD.RekrutteringHudkreft | Slimhinneneoplasma i munnhulen | MykvevsneoplasmaIsrael
-
Alpha Tau Medical LTD.RekrutteringProstata adenokarsinomIsrael
-
Alpha Tau Medical LTD.European Organisation for Research and Treatment of Cancer - EORTCHar ikke rekruttert ennåPlateepitelkarsinom i hode og nakke | PlateepitelkarsinomIsrael
-
Alpha Tau Medical LTD.RekrutteringHudkreft | Slimhinneneoplasma i munnhulen | MykvevsneoplasmaIsrael
-
Alpha Tau Medical LTD.AvsluttetMetastatisk brystkreft | Brystkarsinom | Invasiv brystkreft | Fjernmetastaser. PatologiDen russiske føderasjonen
-
Alpha Tau Medical LTD.FullførtPlateepitelkarsinom i hudenItalia
-
Alpha Tau Medical LTD.RekrutteringHudkreft | Slimhinneneoplasma i munnhulen | MykvevsneoplasmaItalia
-
Alpha Tau Medical LTD.Aktiv, ikke rekrutterendeHudkreft | Slimhinneneoplasma i munnhulen | MykvevsneoplasmaIsrael
-
Alpha Tau Medical LTD.RekrutteringHudkreft | Slimhinneneoplasma i munnhulen | MykvevsneoplasmaIsrael